Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) grows in line with its trailing trend
Q1 FY2026 weighted avg shares (diluted) of 126.63M shares rose 0.4% year over year, in line with the +0.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.4% toward the trailing-twelve-month pace of +0.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 126.26M USD
- Year-over-year change
- +0.7%
- 4-year CAGR
- +10.6%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 126.26M | +0.7% |
| FY2024 | 2024-12-31 | 125.43M | +0.4% |
| FY2023 | 2023-12-31 | 124.92M | +0.3% |
| FY2022 | 2022-12-31 | 124.59M | +47.5% |
| FY2021 | 2021-12-31 | 84.46M | — |
Weighted Avg Shares (Diluted) vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's LTM Mar 2026 weighted avg shares (diluted) of 126.35M shares is the 3rd highest of the 11 companies compared; the peer median is 51.72M shares.
- Its year-over-year change of +0.5% is the lowest of 11, against a peer median of +18.9%.
- Over three fiscal years its annual growth of +0.4% compares with a peer median of +17.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 167.44M | +37.0% | +15.3% | |
| LTM Mar 2026 | 158.02M | +71.7% | +50.6% | |
| LTM Mar 2026 | 126.35M | +0.5% | +0.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | 98.81M | +34.9% | +76.1% |
| LTM Mar 2026 | 64.63M | +7.9% | +14.8% | |
| LTM Mar 2026 | 62.52M | +2.9% | +23.4% | |
| LTM Mar 2026 | 40.92M | +29.8% | +18.6% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | 32.39M | +0.9% | +13.4% |
| LTM Mar 2026 | 27.53M | +1.8% | +0.4% | |
| LTM Mar 2026 | 21.37M | +0.6% | +1.2% | |
| LTM Mar 2026 | 10.86M | +66.5% | +40.6% | |
| Peer median (excluding NAUT) | 51.72M | +18.9% | +17.0% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Gross Profit | (2.84M) | (3.42M) | (5.71M) | (6.35M) | (6.47M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 26.51M | 36.46M | 47.25M | 50.48M | 41.11M |
| Selling, General & Admin | 21.15M | 23.75M | 28.9M | 31M | 25.73M |
| Operating Expenses | 47.66M | 60.2M | 70.45M | 75.12M | 60.37M |
| Depreciation & Amortization | 2.84M | 3.42M | 1.85M | 6.35M | 6.47M |
| EBITDA | (47.47M) | (54.51M) | (61.83M) | (64.43M) | (52.54M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.5M) | (63.62M) | (76.15M) | (81.48M) | (66.84M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 329K | 5.82M | 12.55M | 10.78M | 7.87M |
| Interest Expense | 0 | 5.82M | 0 | 0 | 0 |
| Other Income / Expenses | 183K | 5.69M | 12.48M | 10.7M | 7.84M |
| Income Before Tax | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| EPS (Diluted) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| Weighted Avg Shares | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M |
| Weighted Avg Shares (Diluted) | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.